Barclays PLC Boosts Holdings in Seer, Inc. (NASDAQ:SEER)

Barclays PLC raised its holdings in shares of Seer, Inc. (NASDAQ:SEER) by 34.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,426 shares of the company’s stock after acquiring an additional 16,382 shares during the quarter. Barclays PLC’s holdings in Seer were worth $127,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Acadian Asset Management LLC increased its holdings in Seer by 35.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,802,106 shares of the company’s stock valued at $3,024,000 after acquiring an additional 472,283 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Seer by 194.9% during the third quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock worth $252,000 after buying an additional 84,515 shares in the last quarter. Palumbo Wealth Management LLC grew its holdings in shares of Seer by 15.1% during the third quarter. Palumbo Wealth Management LLC now owns 122,292 shares of the company’s stock worth $241,000 after buying an additional 16,001 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seer during the second quarter worth about $148,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Seer during the second quarter worth about $133,000. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Price Performance

Shares of NASDAQ SEER opened at $2.41 on Thursday. The company has a market cap of $142.11 million, a PE ratio of -1.85 and a beta of 1.57. Seer, Inc. has a 12 month low of $1.51 and a 12 month high of $2.63. The company has a 50-day simple moving average of $2.34 and a 200-day simple moving average of $1.98.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.